RxAdvocate November, 2022 — Newsletter

Home > Newsletter  > RxAdvocate November, 2022 — Newsletter

February 2 RxAdvocate November, 2022 — Newsletter

Posted at 21:14h in Newsletter by
0 Likes

November Stories:

  • Opiod Epidemic Lawsuits
  • Overdose Reversal OTC
  • New Discount Card Partnership

CVS, Walgreens and Walmart agree to pay $12B to settle opiod epidemic lawsuits

Earlier this month, CVS, Walgreens and Walmart agreed to pay more than $12 billion to settle numerous cases brought forth by state and local governments.
Attorney generals in six states allege the named pharmacy providers mismanaged the highly addictive painkillers over the course of two decades resulting in over 500,000 deaths in the U.S. alone.

FDA moves to boost access to overdose reversal with OTC endorsement

Development of OTC overdose reversal drugs may be on the horizon.
The FDA's preliminary assessment of non-prescription naloxone is one of the first steps to easing the availability of the life saving drug.
Currently, all 50 states allow pharmacists to dispense naloxone without a doctor's prescription.

New Discount Card Partnership

Earlier this month, GoodRx and Cigna's Express Scripts announced their exclusive partnership to provide discount drug cards to the PBM's members with the Price Assure program.
Starting in 2023, GoodRx will incorporate its pricing into Express Scripts commercial pharmacy benefit for generic medications. The integration will automatically apply the lowest cost for patients by comparing the GoodRx price to the benefit price through Express Scripts. Any out-of-pocket expense by the patient will also apply to the deductible to keep all spending visible within the pharmacy benefit.

Contact us

Visit us on the web at www.rxconnectionllc.com.
If you would like additional information on our services please contact:
Orlando Neal — Principal
Orlando.Neal@rxconnectionllc.com